Answers are grounded in this paper and cite their sources.
Qualitative study explores barriers and facilitators to implement mindfulness therapy for IBD, indicating the need for a strong business case.
Background Our recent trial studying mindfulness-based cognitive therapy (MBCT) for Inflammatory Bowel Disease (IBD) patients demonstrated reductions in psychological distress and improvements in well-being. Building on these findings, the present study aimed to explore barriers and facilitators for implementation and scenarios to overcome these. Methods We conducted a sequential two-part study consisting of qualitative interviews followed by a survey. Semi-structured interviews were conducted with key stakeholders ( n = 32) on barriers and facilitators for implementation. The Consolidated Framework for Implementation Research guided data collection and framework analysis. Based on interview outcomes, implementation scenarios were formulated and presented in a survey to stakeholders ( n = 21) to explore their perspectives on the most suitable scenario. Results Key barriers identified were scepticism and misconceptions about MBCT and its lack of evidence, and limited funding, time, and perceived competency to discuss mental health in medical consultations. Facilitators included the presence of a local champion, growing attention to lifestyle factors in society and healthcare, and the group-based design of MBCT providing peer support. Stakeholders preferred integrating MBCT within a regional network, but opinions differed. Irrespective of the preferred scenario, stakeholders emphasized the need for a strong business case, including evidence on long-term (cost-)effectiveness, to secure broad support and insurance coverage. Conclusions Although implementing MBCT for IBD patients is worthwhile, several prominent barriers currently hinder this process. A strong business case is needed to gain broad support and insurance coverage. Further research is required to determine the most suitable and feasible implementation scenario and associated strategies. Clinical trial number not applicable.
No takes yet. Share an insight, caveat, or question.
Bosman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: